Elly Barry, MD, MMSc

Elly Barry is a board-certified pediatrician and pediatric hematologist/oncologist, currently serving as the Senior Vice President, Clinical Development at Day One Biopharmaceuticals. Prior to Day One, while at Pfizer, she contributed to the development of PIPs/PPSRs across a number of compounds, including bosutinib, gemtuzumab ozogamicin, inotuzumab ozogamizin, and sunitinib.

Elly received her MD degree from Yale University School of Medicine in New Haven, before completing residency training in pediatrics at Tufts-New England Medical Center/Floating Hospital for Children in Boston, and fellowship training in pediatric hematology/oncology at Boston Children’s Hospital/Dana-Farber Cancer Institute in Boston. She remained on staff at DFCI as an Instructor in Pediatric Hematology/Oncology and Bone Marrow Transplantation, while obtaining a Masters in Medical Science degree from Harvard Medical School. Her previous industry roles at Genzyme and Millennium have focused on the early and late development of drugs for hematologic malignancies, breast, and renal cancers.